EyeWorld Korea December 2025 Issue

Media placement sponsored by Carl Zeiss Meditec AG

Insights from Clinical Experience with a Novel Trifocal IOL

31 For more than eight years, Joon Young Hyon, MD, PhD (South Korea) has preferred implanting the AT LISA tri 839MP due to its high visual quality leading to high long-term patient satisfaction. Recently, ZEISS launched the new trifocal hydrophobic IOL, AT ELANA 841P, based on the optical design of the AT LISA tri IOL, and Prof. Hyon has found excellent outcomes implanting this IOL. With an enhanced trifocal design, the AT ELANA is based on a C-loop platform and comes fully preloaded. The IOL has focal planes at 40 cm and 80 cm, providing patients with a continuous range of vision from far to near. With increased overall light trans mission due to the diffractive structure and increased light alloca tion towards near vision, patients are able to experience improved near-to-intermediate vision without compromising far vision. “When you look at the light distribution graph, you can see that there is more light reaching the AT ELANA IOL compared to the AT LISA tri IOL,” Prof. Hyon said. Changing the light distribution by sending more light to near vision has a stronger impact on near visual acuity without impacting distance and intermediate visual acuity for AT ELANA. “This IOL offers increased light transmission efficiency with a higher allocation of light towards near vision,” Prof. Hyon continued. “There is no apodization or switch to monofocal distance-dominant zones.” A recently published clinical study 1 with AT ELANA implanted in 252 eyes found that, at 3-month follow-up, visual acuity was better than +0.20 logMAR across a defocus range of +1.3 D to -3.2 D. Additionally, on average, visual acuity was +0.04 logMAR for near vision (40 cm). The AT ELANA IOL also is designed with a neutral spherical aberration profile. “This lens is suitable for patients regardless of their corneal spherical aberration,” Prof. Hyon said. “It has a robust performance under decentration and tilt caused by ocular imperfec tions compared to lenses with spherical aberration-correcting IOL designs.” In an aberration-neutral design, there is a decrease in the negative impact of decentration and tilt on the image quality while also not impacting the net spherical aberration of the eye. “The modulation transfer function (MTF) remains very stable through decentration,” Prof. Hyon said. Another optical design feature of the AT ELANA IOL is its patented Smooth Micro Phase (SMP) technology, which aims to provide a better image quality due to reduced light scattering and related photic phenomena. In conventional diffractive IOL designs, an ideal surface contains steps with sharp angles that cannot be manu factured perfectly using current technologies. “As a consequence, a certain amount of light will be scattered in undefined directions causing glare,” Prof. Hyon remarked. The patented SMP technology “ The PathFinder™ is a great tool to help us quickly flag retinal pathology so that our patients get the appropriate lenses that their eyes deserve. ” Ronald Yeoh, FRCS, FRCOphth, DO, FAMS

check a scan and having to face unexpected poor outcomes are two things that cataract surgeons should not have to deal with in their day-to-day clinical experience. “The PathFinder™ is a great tool to help us quickly flag retinal pathology so that our patients get the appropriate lenses that their eyes deserve,” Dr. Yeoh said. “It’s an excellent technology,” Smita Agarwal, MBBS, MS, BSc, FRANZCO (Australia), chair of the session, added. “The result is that you can spend more time talking with the patient.” For Dr. Yeoh, using the PathFinder™ is part of his routine workup. “The PathFinder™ saves us time and protects us from missing parafo veal disease on the OCT scan,” he said. “If you are not really good at looking at macular scans, the PathFinder™ is a useful guide.” The ZEISS CIRRUS PathFinder™ automatically flags pathologies such as intra-retinal fluid, or, in the case above, early onset dry AMD in the form of Drusen.

EyeWorld Asia-Pacific | December 2025